摘要
目的 探讨雷帕霉素(rapamycin)与顺铂(cisplatin)联合使用对趋化因子CCL19调节头颈鳞状细胞癌细胞活性的影响.方法 应用甲基噻唑基四唑(MTT)法及流式细胞仪检测顺铂及雷帕霉素对CCL19诱导后人头颈鳞状细胞癌淋巴结转移细胞系(PCI-4B、PCI-37B)生长抑制作用、细胞凋亡作用和细胞周期变化.使用Calcusyn软件计算两种药物(浓度比为80:1)联合使用时的剂量效应参数及联合指数(combination index,CI),使用SPSS 11.0软件包进行统计分析.结果 顺铂及雷帕霉素可以分别提高CCL19作用后细胞的生长抑制率(CCL19+顺铂作用后两细胞系的生长抑制率为21.22%±2.68%和22.76%±2.79%,CCL19+雷帕霉素作用后为19.46%±2.54%和20.6%±4.38%)、细胞G1期比例(CCL19+顺铂作用后两细胞系的G1期比例为72.14%±2.66%和76.39%±1.45%,CCL19+雷帕霉素作用后为75.26%±5.92%和74.00%±1.51%)和凋亡率(CCL19+顺铂作用后两细胞系的凋亡率9.59%±0.86%和7.55%±0.66%,CCL19+雷帕霉素作用后为8.21±1.80%和6.26±0.78%).两种药物浓度比为80:1联合使用时,PCI-4B细胞在半数抑制量(inhibitory concentration 50%,IC50)以下,CI<1,IC75以上CI>1;PCI-37B则在IC75以下CI<1,IC90以上CI>1.结论 顺铂及雷帕霉素均有抑制CCL19对人头颈鳞状细胞癌淋巴结转移细胞的活性调节作用,并且二者联合使用存在协同作用.
Objective To investigate the synergistic effects of rapamycin and cisplatin on head and neck squamous cancer cells regulated by chemokine( C-C motif) ligand 19 (CCL19). Methods The role of rapamycin and cisplatin was detected on cell-cycle and apoptosis in CCL19 induced PCI-4B and PCI-37B cells by methyl thiazolyl tetrazolium (MTT) and flow cytometry(FCM). Dose-effect relationship parameters and combination index(CI) were calculated on the median-effect equation and multiple drug effect equation using computer software CalcuSyn. Statistical analysis was performed by the unpaired student's t-test.Results Rapamycin and cisplatin could respectively increase the growth arrest, the proportion of G1 phase and apoptosis of CCL19 induced cancer cells (P <0. 05 ). Under inhibitory concentration 50% (IC50), CI was less than 1, and in IC75, it was more than 1 in PCI-4B cells. In PCI-37B cells, under IC75, CI was less than 1, and in IC90, it was more than 1. Conclusions Rapamycin and cisplatin can inhibit CCL19-regulated PCI-4B and PCI-37B cells' survival. The two drugs have synergistic effects when used in combination.
出处
《中华口腔医学杂志》
CAS
CSCD
北大核心
2011年第4期197-200,共4页
Chinese Journal of Stomatology
基金
国家自然科学基金(30672331)
辽宁省教育厅高等学校科研项目计划(2009A755)